Quantcast

Latest Tardive dyskinesia Stories

2014-08-06 16:29:09

SUCCESSFUL END-OF-PHASE II MEETING FOR NBI-98854 IN TARDIVE DYSKINESIA SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2014. For the second quarter of 2014, the Company reported a net loss of $13.4 million, or $0.18 loss per share, compared to a net loss of $12.2 million, or $0.18 loss per share, for the same period in 2013. For the six months ended June 30, 2014, the Company...

2014-06-11 08:28:27

DATA FROM KINECT 1 AND KINECT 2 TARDIVE DYSKINESIA STUDIES SAN DIEGO, June 11, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that on June 11, 2014, two scientific posters associated with its study of NBI-98854 in Phase IIb clinical trials of tardive dyskinesia patients, will be presented at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders in Stockholm Sweden. This annual meeting brings together over 5,000 clinicians and...

2014-02-25 08:31:24

DATA FROM KINECT 1 AND KINECT 2 STUDIES WILL BE PRESENTED SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement...

2014-01-09 16:25:37

OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this...

2014-01-06 16:27:45

Plans to submit end of phase II meeting request to FDA SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central...

2013-03-26 23:03:15

According to court documents, on March 7th, 2013 a Louisiana woman asked the US Supreme Court to hear her case alleging neurological damage from generic Reglan. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Reglan side effects. San Diego, CA (PRWEB) March 26, 2013 AttorneyOne.com, a recognized authority on law, updated the website recently...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.